Cell Signaling & Oncology
The signaling pathways controlling cell growth and differentiation are almost invariably altered in cancer. During the course of tumor progression, cancer cells acquire a number of characteristic alterations. These include the capacities to proliferate independently of exogenous growth-promoting or growth-inhibitory signals, to invade surrounding tissues and metastasize to distant sites, to elicit an angiogenic response, and to evade mechanisms that limit cell proliferation, such as apoptosis and replicative senescence. These properties reflect alterations in the cellular signaling pathways that in normal cells control cell proliferation, motility, and survival. These interconnected pathways are being deciphered, but understanding the alterations that lead to cancer and correcting them is a substantial challenge. Among the key pathways are those controlling cell proliferation, which coordinate a response to the cellular environment, with the mTOR kinase as a critical node. Tumour development is influenced by infections and inflammation, and the complex role of the nuclear factor-B transcription factors is being unravelled. Expansion of tumour cells depends on nutrient supply and vascularization, which is orchestrated by the transcription factor known as HIF. And the metastatic spread of primary tumours to other organs is facilitated by many signaling pathways[1],[2].
Cell Signaling and Oncology products Library
For your convenience, you can order a library of all of our Cell Signaling and Oncology research related products. Make your personal library by cherry picking products of your interest from our comprehensive list (>800 products), or order all together not to miss any. The libraries will be shipped as 10 mM solutions (in DMSO, 250 µL of each selected Axon Ligand™) on a 96-well microtiter plate with a clear map of its contents.
Simply download our comprehensive list of epigenetics products below (Microsoft Excel (.xls)), check the products to be included, and return your list to order the library of your preference.
 Axon 5051 - Cell signaling and Oncology Library.xls |
|
[1] A. Eccleston, R. Dhand. Signalling in cancer. Nature 441, 423, editorial note
[2] G.S. Martin. Cell signaling and cancer. Cancer Cell. 2003 Sep;4(3):167-74.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 3729 | ABBV-CLS-484 hydrochloride | Inhibitor of phosphatase PTPN1/N2 (Protein Tyrosine Phosphatase Non-Receptor Type 1 and 2), | Inquire | |
| 2880 | ABC294640 | Selective and orally available SphK2 (or SK2) inhibitor | €125.00 | |
| 1873 | Abiraterone | Inhibitor of CYP17A1 | €90.00 | |
| 1874 | Abiraterone acetate | Prodrug of Abiraterone; Inhibitor of CYP17A1 | €90.00 | |
| 3040 | Abivertinib | Potent oral, irreversible, third-generation EGFR TKI with selectivity for mutant EGFRs | €95.00 | |
| 3631 | ABR-238901 | Potent S100A8/A9 blocker | €170.00 | |
| 2141 | ABT 199 | Potent, orally bioavailable BCL-2-selective inhibitor | €70.00 | |
| 2289 | ABT 702 | The first, non-nucleoside adenosine kinase (ADK) inhibitor | €120.00 | |
| 1638 | ABT 869 | PDGFR, c-KIT and VEGFR tyrosine kinase inhibitor | €85.00 | |
| 3821 | ABT-263 | Potent, selective and orally bioavailable inhibitor of B-cell lymphoma-2 (BCL-2) family proteins | Inquire | |
| 4141 | Acalabrutinib | Orally active, irreversible, and highly selective second-generation BTK inhibitor | Inquire | |
| 2857 | Acalisib | PI3K inhibitor (p110 δ specific) | €120.00 | |
| 3590 | ACT001 | PAI-1 inhibitor | €210.00 | |
| 3039 | ACY-241 | Selective and orally available HDAC6 inhibitor | €120.00 | |
| 2275 | AdipoRon | Orally active small-molecule AdipoR agonist | €80.00 | |
| 2552 | Adjudin | Non-hormonal male contraceptive with anti-proliferative activity | €125.00 | |
| 3687 | ADU-S100 | Cyclic dinucleotide (CDN) agonist (activator) of Stimulator of Interferon Genes (STING) | Inquire | |
| 1653 | AEE 788 | EGFR, ErbB2 and VEGFR tyrosine kinase inhibitor | €80.00 | |
| 1291 | AEG 3482 | JNK inhibitor | €90.00 | |
| 1414 | AG 013736 | PDGFR,c-KIT and VEGFR tyrosine kinase inhibitor | €50.00 | |
| 1529 | AG 014699 | PARP1 inhibitor | €60.00 | |
| 1378 | AG 490 | JAK2 inhibitor | €65.00 | |
| 2746 | AG-120 | IDH1 mutant enzyme inhibitor | €125.00 | |
| 2745 | AG-221 | IDH2 mutant enzyme inhibitor | €95.00 | |
| 3515 | AG-270 | First-in-class, highly potent, selective, orally bioavailable MAT2A inhibitor | €180.00 | |
| 4276 | AG14361 | Potent PARP1 inhibitor | €130.00 | |
| 2122 | AGI 5198 | Inhibitor of R132 mutant isocitrate dehydrogenase 1 (IDH1) | €60.00 | |
| 2274 | AGI 6780 | Potent and selective inhibitor of the tumor-associated mutant IDH2 (R140Q) | €90.00 | |
| 2389 | AICAR | Potent AMPK activator and inducer of differentiation of NSCs | €45.00 | |
| 2031 | AIM 100 | Specific inhibitor of Ack1 tyrosine kinase (also known as TNK2) | €95.00 | |